CD19 and diffuse large B-cell lymphoma: DLBCL patients who experience disease relapse after 12 months from therapy discontinuation and are strong candidates for stem cell transplantation should receive aggressive chemotherapy as a bridge to transplant, whereas those who are not strong candidates for the procedure can benefit from CD19-directed CAR-T cell therapy, bispecific antibodies, or other treatment regimens.